Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Joshua M. Thiede"'
Autor:
Abigail R. Gress, Christine E. Ronayne, Joshua M. Thiede, David K. Meyerholz, Samuel Okurut, Julia Stumpf, Tailor V. Mathes, Kenneth Ssebambulidde, David B. Meya, Fiona V. Cresswell, David R. Boulware, Tyler D. Bold
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
Abstract After Mycobacterium tuberculosis (Mtb) infection, many effector T cells traffic to the lungs, but few become activated. Here we use an antigen receptor reporter mouse (Nur77-GFP) to identify recently activated CD4 T cells in the lungs. These
Externí odkaz:
https://doaj.org/article/ca259876e3be47d9b437b62b4a3c7cd7
Autor:
Obinna C. Ubah, Eric W. Lake, Gihan S. Gunaratne, Joseph P. Gallant, Marie Fernie, Austin J. Robertson, Jonathan S. Marchant, Tyler D. Bold, Ryan A. Langlois, William E. Matchett, Joshua M. Thiede, Ke Shi, Lulu Yin, Nicholas H. Moeller, Surajit Banerjee, Laura Ferguson, Marina Kovaleva, Andrew J. Porter, Hideki Aihara, Aaron M. LeBeau, Caroline J. Barelle
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Shark antibodies (Variable New Antigen Receptors, VNARs) are the smallest naturally occurring antibody fragments. Here, the authors screen a VNAR phage display library against the SARS-CoV2 receptor binding domain (RBD) and identify VNARs that neutra
Externí odkaz:
https://doaj.org/article/d533a0ef137944a582f18b4def8a849b
Autor:
Joshua M. Thiede, Nicholas A. Dillon, Michael D. Howe, Ranee Aflakpui, Samuel J. Modlin, Sven E. Hoffner, Faramarz Valafar, Yusuke Minato, Anthony D. Baughn
Publikováno v:
mBio, Vol 13, Iss 1 (2022)
ABSTRACT Pyrazinamide (PZA) plays a crucial role in first-line tuberculosis drug therapy. Unlike other antimicrobial agents, PZA is active against Mycobacterium tuberculosis only at low pH. The basis for this conditional drug susceptibility remains u
Externí odkaz:
https://doaj.org/article/8ee355f2a62d421f881cdc358d63bc6d
Autor:
Yusuke Minato, Daryl M. Gohl, Joshua M. Thiede, Jeremy M. Chacón, William R. Harcombe, Fumito Maruyama, Anthony D. Baughn
Publikováno v:
mSystems, Vol 4, Iss 4 (2019)
ABSTRACT A better understanding of essential cellular functions in pathogenic bacteria is important for the development of more effective antimicrobial agents. We performed a comprehensive identification of essential genes in Mycobacterium tuberculos
Externí odkaz:
https://doaj.org/article/ad5d108f32c64e50b9dd00178fb3a8e5
Autor:
Malcolm S. Cole, Michael D. Howe, Joseph A. Buonomo, Sachin Sharma, Elise A. Lamont, Scott I. Brody, Neeraj K. Mishra, Yusuke Minato, Joshua M. Thiede, Anthony D. Baughn, Courtney C. Aldrich
Publikováno v:
Chemistry (Weinheim an der Bergstrasse, Germany). 28(51)
Tuberculosis (TB) is a leading source of infectious disease mortality globally. Antibiotic-resistant strains comprise an estimated 10 % of new TB cases and present an urgent need for novel therapeutics. β-lactam antibiotics have traditionally been i
Autor:
Vineet Joag, Stephen D O'Flanagan, Joshua M. Thiede, Clare F. Quarnstrom, Clayton K. Mickelson, Marc K. Jenkins, J. Michael Stolley, William E. Matchett, Tyler D. Bold, David Masopust, Michelle N Vu, Vaiva Vezys, Frances K. Shepherd, Vineet D. Menachery, Jennifer A Walter, Samuel Becker, Sathi Wijeyesinghe, Ryan A. Langlois, Eyob Weyu, Andrew G. Soerens
Publikováno v:
bioRxiv
J Immunol
J Immunol
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Neutralizing Abs target the receptor binding domain of the spike (S) protein, a focus of successful vaccine efforts. Concerns have arisen that S-sp
Autor:
Anthony D. Baughn, Ranee Aflakpui, Faramarz Valafar, Yusuke Minato, Michael D. Howe, Samuel J. Modlin, Sven E Hoffner, Nicholas Dillon, Joshua M. Thiede
Pyrazinamide (PZA) plays a crucial role in first-line tuberculosis drug therapy. Unlike other antimicrobial agents, PZA is only active against Mycobacterium tuberculosis at low pH. The basis for this conditional drug susceptibility remains undefined.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::646d0d71f234f399d21a4f0413630754
https://doi.org/10.1101/2021.02.17.431758
https://doi.org/10.1101/2021.02.17.431758
Autor:
J. Michael Stolley, Peter J. Southern, Siddheshvar Bhela, Thamotharampillai Dileepan, Maxim C.-J. Cheeran, Vineet Joag, Marc K. Jenkins, Sathi Wijeyesinghe, Joshua M. Thiede, Luca Schifanella, Jules A. Sangala, Clare F. Quarnstrom, Geoffrey T. Hart, Stephen D O'Flanagan, Sung-Wook Hong, Venkatramana D. Krishna, William E. Matchett, Noah V. Gavil, David Masopust, Sailaja Gangadhara, Tyler D. Bold, Eyob Weyu, Ryan A. Langlois, Vaiva Vezys, Rama Rao Amara, Andrew G. Soerens
Publikováno v:
J Immunol
The magnitude of SARS-CoV-2–specific T cell responses correlates inversely with human disease severity, suggesting T cell involvement in primary control. Whereas many COVID-19 vaccines focus on establishing humoral immunity to viral spike protein,
Autor:
Tyler D. Bold, Jessica K. Fiege, Ryan A. Langlois, Thomas J. Gniadek, Abigail R Gress, William E. Matchett, Marc K. Jenkins, Kathryn A. Pape, Joshua M. Thiede, Vineet D. Menachery
Publikováno v:
Transfusion
bioRxiv
bioRxiv
BACKGROUND: The transfer of passive immunity with convalescent plasma is a promising strategy for treatment and prevention of COVID-19, but donors with a history of nonsevere disease are serologically heterogenous. The relationship between SARS-Cov-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::503109af3ab0e302b1e042bde4e03429
https://europepmc.org/articles/PMC7995753/
https://europepmc.org/articles/PMC7995753/
Autor:
Daniel E. Agnew, Kelly M. Wetmore, Tippapha Pisithkul, Ryan L. Clark, Daniel Amador-Noguez, Morgan N. Price, Jacqueline M. Rand, Joshua M. Thiede, Christopher R. Mehrer, Yumi Suh, Andrew L. Markley, Candace E. Campbell, Adam P. Arkin, Brian F. Pfleger, Adam M. Deutschbauer, Jayashree Ray
Publikováno v:
Nature microbiology
Rand, JM; Pisithkul, T; Clark, RL; Thiede, JM; Mehrer, CR; Agnew, DE; et al.(2017). A metabolic pathway for catabolizing levulinic acid in bacteria. Nature Microbiology, 2(12), 1624-1634. doi: 10.1038/s41564-017-0028-z. Lawrence Berkeley National Laboratory: Retrieved from: http://www.escholarship.org/uc/item/7wj2z10w
Rand, JM; Pisithkul, T; Clark, RL; Thiede, JM; Mehrer, CR; Agnew, DE; et al.(2017). A metabolic pathway for catabolizing levulinic acid in bacteria. Nature Microbiology, 2(12), 1624-1634. doi: 10.1038/s41564-017-0028-z. Lawrence Berkeley National Laboratory: Retrieved from: http://www.escholarship.org/uc/item/7wj2z10w
© 2017 The Author(s). Microorganisms can catabolize a wide range of organic compounds and therefore have the potential to perform many industrially relevant bioconversions. One barrier to realizing the potential of biorefining strategies lies in our